SW1115C3

SW1115C3 is a personalized neoantigen mRNA cancer vaccine developed by Stemirna Therapeutics. It is designed for the treatment of patients with advanced malignant solid tumors, including esophageal carcinoma and non-small cell lung cancer (NSCLC). The vaccine utilizes mRNA technology to encode patient-specific tumor neoantigens, which are identified through genomic sequencing of the individual's tumor. Upon subcutaneous administration, the mRNA is translated into neoantigen proteins that act as immunostimulants, triggering a targeted T-cell immune response against the patient's specific tumor profile. As of early 2024, clinical development of the vaccine was reported to be on hold.

Other names

Neoantigen mRNA Personalised Cancer Vaccine SW1115C3